Health Secretary Kennedy Launches Sweeping Internal Probe into Vaccine Safety

2026-05-11 politics

Washington, Tuesday, 12 May 2026.
Despite public silence, Health Secretary Kennedy is quietly driving a $50 million internal federal probe into vaccine safety, signaling potential regulatory shifts that could disrupt the pharmaceutical industry.

The Architecture of the Department’s Probe

As of early May 2026, the Department of Health and Human Services (HHS) is executing an extensive research initiative directed by Health Secretary Robert F. Kennedy Jr. [1][2]. The effort, which carries an estimated cost of $40 million to $50 million for the Centers for Disease Control and Prevention (CDC), is designed to investigate Kennedy’s long-held theory that vaccines are responsible for an epidemic of chronic diseases, including autoimmune and neurological disorders such as autism [1][2]. To manage this massive data undertaking, career scientists from the Food and Drug Administration (FDA) and the CDC are working alongside external data contractors who have been granted access to millions of patient medical records [1][2].

Political Calculations Ahead of the 2026 Midterms

The quiet nature of this internal probe is not coincidental. The White House has instructed Kennedy to tone down his public criticisms of vaccines, driven by Republican anxieties that an overt anti-vaccine agenda could prove politically damaging in the upcoming November 2026 midterm elections [1][3]. Internal and external polling has indicated that the Trump-Kennedy stance on vaccines is currently unfavorable among the broader electorate, prompting a strategic pivot toward administrative action rather than public campaigning [3].

Personnel Upheaval and Scientific Pushback

The execution of Kennedy’s agenda has triggered significant friction within federal health agencies. The ouster of agency director Susan Monarez by Kennedy prompted the resignation of Daniel Jernigan and several other senior CDC leaders [2]. Critics of the administration point to potential conflicts of interest within the new leadership. Dr. Kulldorff, for instance, previously joined Kennedy in 2024 litigation against pharmaceutical giant Merck, where he was compensated $400 per hour as an expert witness [2].

A Broadening Front of Regulatory Challenges

The administration’s efforts to reshape vaccine policy extend into the courts. As of May 10, 2026, HHS is appealing a federal district-court injunction that temporarily halted updates to the national immunization schedule [5]. The injunction resulted from a lawsuit by the American Academy of Pediatrics, which successfully argued that HHS bypassed the notice-and-comment procedures mandated by the Administrative Procedure Act [5]. The frozen updates, originally approved by the Advisory Committee on Immunization Practices, were intended to expand the use of newer conjugate vaccines and modify booster-dose timing for adolescents [5].

Sources

Healthcare policy Pharmaceutical industry